The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Hypoglycemic Coma in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib

Sunitinib 치료 중인 전이성 신세포암 환자에서 발생한 저혈당성 혼수

  • Cho, Meyoung (Department of Internal Medicine, Gunsan Medical Center) ;
  • Shim, Hyeok (Department of Internal Medicine, Wonkwang University School of Medicine) ;
  • Park, Moo-Rim (Department of Internal Medicine, Wonkwang University School of Medicine)
  • 조미영 (군산의료원 내과) ;
  • 심혁 (원광대학교 의과대학 내과학교실) ;
  • 박무림 (원광대학교 의과대학 내과학교실)
  • Received : 2014.01.27
  • Accepted : 2014.03.28
  • Published : 2014.10.01
⟨ Previous Next ⟩

Abstract

We present a patient with type 2 diabetes mellitus and metastatic renal cell carcinoma who developed severe hypoglycemia and metabolic encephalopathy after sunitinib treatment. Sunitinib, a multi-target tyrosine kinase inhibitor, is used to treat metastatic renal cell carcinoma. Sunitinib-induced hypoglycemia has been reported and there are rare case reports of severe hypoglycemia due to sunitinib. Therefore, glycemic control should be monitored closely in diabetic patients treated with sunitinib.

전이성 신세포암을 진단받고 sunitinib으로 치료 중이던 2형 당뇨병 환자에서 저혈당과 저혈당에 의한 대사성 뇌병증을 경험하였다. Sunitinib은 다표적 tyrosin kinase 억제제로 전이성 신장암의 치료에 사용되고 있으며 저혈당을 유발시킬 수 있다. 비록 sunitinib과 관련된 중증 저혈당의 보고는 드물지만, sunitinib 치료를 받는 당뇨병 환자들에서 혈당 조절은 매우 면밀히 관찰되어야 할 것이다.

Keywords

References

  1. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. https://doi.org/10.1200/JCO.2005.02.2574
  2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. https://doi.org/10.1056/NEJMoa065044
  3. Billemont B, Medioni J, Taillade L, et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008;99:1380-1382. https://doi.org/10.1038/sj.bjc.6604709
  4. Demirci A, Bal O, Durnali A, et al. Sunitinib-induced severe hypoglycemia in a diabetic patient. J Oncol Pharm Pract 2013 Oct 24 [Epub]. DOI:10.1177/1078155213508441.
  5. Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011;17:197-202. https://doi.org/10.1177/1078155210378913
  6. Oh JJ, Hong SK, Joo YM, et al. Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2012;42:314-317. https://doi.org/10.1093/jjco/hys002
  7. Templeton A, Brändle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 2008;19:824-825.
  8. Hägerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 2007;21:618-628. https://doi.org/10.1096/fj.06-6910com
  9. Lee Y, Jung HS, Choi HJ, et al. Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: a case report. Diabetes Res Clin Pract 2011;93:e68-70. https://doi.org/10.1016/j.diabres.2011.04.011
  10. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249. https://doi.org/10.2337/diacare.28.5.1245

Cited by

  1. Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature vol.38, pp.6, 2016, https://doi.org/10.3892/ijmm.2016.2776